[Retracted] The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia

Table 2

Comparison between the two groups after treatment.

	Variable	BUN (mmol/L)	CR (μmol/L)	eGFR (ml/min/1.73 m^2)	UA (μmol/L)	Urine microalbumin/CR (mg/g)	Urine NGAL/CR (μg/g)	Urine KIM-1/CR (μg/g)
Baseline	Febuxostat	5.9 ± 1.9	80.7 ± 19.6	99 ± 14	555 ± 81	50 ± 15	12.1 ± 2.4	2.4 ± 0.5
	Control	6.1 ± 1.9	78.1 ± 24.7	102 ± 13	570 ± 82	48 ± 18	13.8 ± 4.1	2.6 ± 0.6
	value	0.720	0.696	0.465	0.543	0.686	0.089	0.229
Treatment	Febuxostat	5.7 ± 2.0	77.6 ± 24.5	103 ± 17	319 ± 98	24 ± 8	6.7 ± 2.5	1.2 ± 0.3
	Control	6.0 ± 2.1	78 ± 26.3	100 ± 15	568 ± 89	45 ± 17	14.5 ± 4.2	2.8 ± 0.7
	value	0.627	0.958	0.539	<0.001	<0.001	<0.001	<0.001